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Chapter 3
Classical Hodgkin lymphoma (cHL) is characterized by a low number of malignant
cells, called Hodgkin Reed-Sternberg (HRS) cells, surrounded by an abundant infiltrate
of immune cells. Presence of T helper (Th)2 and regulatory T-cells (Treg) in the infil-
trate was shown by staining of T-cell subtype specific transcription factors in cHL tissue
samples1 and by expression of Th2 and Treg specific cytokines in sorted T-cell subsets2.
However, one study revealed a predominant Th1 subpopulation in the microenviron-
ment of cHL based on expression of CXCR3 by flow cytometry3. Differences between
these studies may potentially be explained by heterogeneity between Epstein Barr virus
(EBV) positive and negative cHL cases and by differences in cell composition in relation
to proximity of tumor cells.
In this study we compared the composition of the reactive infiltrate of EBV+ (n=7)
and EBV- cHL (n=7) with each other and with reactive lymph nodes (RLN) for 46 spe-
cific cell types (Supplementary table S1). In addition, we made a distinction between
cells that are located in the close vicinity of tumor cells and cells that are further away.
The characteristics of the study cohort have been described in Table 3.1. The gender dis-
tribution and age range of the cHL patients are comparable with the RLN cohort. There
is no significant difference in ages between the EBV+ and EBV- patients. The majority
of the cHL patients have nodular sclerosis (NS) histology, with in the EBV+ cHL group
relatively more mixed cellularity (MC) cases.
Table 3.1: Characteristics of the study cohorts.
We did not find any significant differences between cHL and RLN in the main cell
populations (B cells, T-cells, natural killer cells (NK) and macrophages)(Supplementary
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Table S2). In contrast to a previous study using immunohistochemistry (range 3-57%)4,
we observed relatively low percentages of macrophages. This might be caused by a less
optimal isolation of macrophages from fresh tissues, resulting in an underrepresentation
of these cells in our flow analysis.
Analysis of different T-cell subpopulations revealed significantly more GITR+CD25+
and FoxP3+CD25+ Treg cells in the CD4+ T-cell subset in both EBV+ and EBV- cHL com-
pared to RLNs (Figure 3.1 A, B). This increase in Treg cells is consistent with a previously
published study5. We observed no significant difference for EBV+ and EBV- cHL in the
percentage of Tregs, suggesting that suppression of the immune response is important
in both EBV+ and EBV- cHL. FoxP3+CD25+CD4+ Tregs were upregulated in EBV+ cHL
cases by immunohistochemistry6. Moreover, upregulation of mRNA levels for Treg as-
sociated markers and cytokines has also been described in EBV+ cHL compared to RLN
and EBV- cHL, especially for T regulatory 1 cells, that produce IL-107. Together these
findings indicate that Tregs are important in all cHL cases, albeit more pronounced in
the microenvironment of EBV+ cHL.
The percentage of CD56+CD16+ NK cells was significantly lower in EBV- cHL com-
pared to RLN and EBV+ cHL (Figure 3.1 C). In addition, we observed significantly more
CD69+, Granzyme B+ and TIA-1+ cells in the CD8+ T-cell subset in EBV+ cHL compared
to RLN and EBV- cHL (Figure 3.1 D-F). Thus, EBV status has a positive correlation with
the percentage of NK cells and activated CD8+ T-cells. This suggests that the presenta-
tion of EBV-derived antigenic peptides within HLA class I molecules triggers anti-viral
immune responses. The number of NK cells can increase upon recognition of virus by
Toll like receptors. The higher numbers of cytotoxic CD8+ T-cells in EBV+ cHL indicates
a Th1 response, since Th1 cells stimulate a cellular immune response and activate CD8+
T-cells. In contrast to the findings of Greaves et al3, we did not find significant increases
in the percentage of CXCR3+ Th1 cells within the CD4+ cells in either EBV+ or in EBV-
cHL.
The combined presence of Tregs and activated CD8+ T-cells raises the questions on
how they can co-exist in cHL and where they are located in respect to the tumor cells. To
answer these questions, we used CD26 to discriminate between T-cells in the area of the
HRS cells, i.e. the CD26- T-cells, and the T-cells that are not in close contact with the HRS
cells, i.e. the CD26+ T-cells2. To confirm the relevance of using CD26 as a marker, we
first stained CD26 in the cHL tissue sections. In NS and Lymphocyte-Rich (LR) subtypes
of cHL, CD26- cells were indeed located in the close vicinity of tumor cells, while CD26+
cells were not observed in the tumor cell areas. In MC, the CD26+ cells were much more
dispersed and were also found close to the tumor cells. Based on these staining results,
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we excluded the MC cases from the subsequent analyses.
We found significantly more CD69+ Th cells in the CD26- T-cell subset indicating that
these cells are more abundant in the tumor cell area (Figure 3.1 G). This suggests trig-
gering of an immune reaction in these cells, because CD69 is an early activation marker.
A similar pattern was observed in EBV+ as well as EBV- cHL. Furthermore, we also
observed more FoxP3+ suppressive Th cells in the tumor cell area in both EBV+ and
EBV- cHL (Figure 3.1 H). These findings are consistent with increased mRNA levels of
Treg associated genes (CTLA4, IL2RA, TNFRSF4 and CCR4) in CD4+CD26- T-cells in
cHL compared to RLN2. So, the Tregs reside in the direct vicinity of the HRS cells and
might inhibit an effective anti-tumor immune response. There were less CD25+ CTLs
around the tumor cells than outside the tumor cell area (Figure 3.1 I). So, although ac-
tivated CTLs are present in the microenvironment of cHL, these cells are not present in
the tumor cell rich areas and thus not effective.
In conclusion, we showed that the main difference in the composition of the microen-
vironment between EBV+ and EBV- cHL patients is caused by increased numbers of both
CD8+ T-cells and NK cells. High numbers of CD4+ Tregs directly surrounding HRS cells
implies that they play an important role in the failure to induce an effective immune
response against the HRS cells of cHL.
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Figure 3.1: Significantly different immune cell populations in classical Hodgkin lymphoma
(cHL). Optimized concentrations of fluorochrome-antibody conjugates were applied on cell sus-
pensions of cHL tissue. Flow cytometry was performed to detect expression levels of those mark-
ers on the reactive cells. (A-F) Significant different immune cell populations between normal lym-
phoid (reactive lymph node, RLN) and Epstein-Barr Virus positive (EBV+) and EBV- cHL (A)
Percentages of GITR+CD25+ in CD4+ cells; (B) FoxP3+CD25+ in CD4+ cells; (C) CD16+ in CD56+
cells; (D) CD69+ in CD8+ cells; (E) Granzyme B+ in CD8+ cells; (F) TIA-1+ in CD8+ cells. An
overview of all subsets tested and of all results has been given in supplementary tables S1-3. Lines
indicate the median percentage for each group. For statistical analysis, Kruskal-Wallis test was
used to compare the difference in all three groups and after multiple testing correction a p-value
of 0.0125 was considered to be significant. Mann-Whitney U test was used as a post hoc test to
identify significant differences in groups. ( ∗ : P<0.05; ∗∗ :P<0.01). (G-I) Cell populations with
significant differences between CD26- and CD26+ T-cells in cHL overall and EBV-stratified sub-
groups. (G) Percentages of CD69+ in CD4+ cells in cHL; (H) FoxP3+ in CD4+ cells in cHL; (I)
CD25+ in CD8+ cells in cHL. Lines indicate the median percentage for each group. For statistical




Supplementary Table S1: Leukocyte subpopulations and antibodies used
46
The microenvironment of cHL: heterogeneity by EBV presence
BD: BD Biosciences; IQ: IQ Products, Groningen, Netherlands; R&D: R&D systems, Min-









Median (Range) %  p value 
(K-W) 
RLN  EBV+  EBV- 
B-cells  CD20+ 37 (27-58)  26 (12-51)  21 (16-47)  0.0526 
T-cells  CD3+ 57 (39-65)  60 (55-90)  64 (50-68)  0.1719 
NK cells  CD56+ 13 (10-18)  13 (7-16)  12 (8-21)  0.9711 
Macrophages CD68+  2 (1-2)  2 (1-3)  2 (1-3)  0.6367 
Th cells  CD4+ 36 (27-49)  41 (11-52)  48 (34-57)  0.1353 
Cytotoxic T cells  CD8+ 20 (14-38)  34 (12-79)  17 (9-22)  0.1498 
CD69+ in CD4+ 42 (21-59)  60 (34-80)  52 (24-71)  0.2112 
 




Suppression of Th cells 
CD69+ in CD8+ 35 (14-51)  52 (42-76)  22 (19-53)  0.0125 
CD25+ in CD8+ 30 (12-32)  29 (9-65)  27 (12-69)  0.7625 
CD25+ in CD4+ 10 (5-21)  22 (11-27)  14 (7-39)  0.0388 
CD127low in CD4+ 15 (5-31)  18 (16-39)  19 (10-44)  0.359 
CD152+ in CD4+ 8 (5-17)  11 (4-20)  8 (4-27)  0.849 
FoxP3+ in CD4+ 11 (7-28)  30 (16-46)  17 (7-30)  0.0193 
GITR+ in CD4+ 17 (10-66)  39 (22-51)  37 (17-66)  0.2182 
Naïve Th cells  CD45RA+ in CD4+ 44 (28-98)  21 (19-37)  36 (17-47)  0.0196 
Th1 cells  CXCR3+ in CD4+ 18 (11-56)  24 (11-55)  33 (18-48)  0.5336 
 
Th2 cells 
CXCR4+ in CD4+ 5 (3-14)  9 (3-16)  4 (3-19)  0.761 
ST2L+ in CD4+ 14 (4-23)  15 (7-21)  12 (5-38)  0.5315 
Truly Naïve Th cells  CCR7+CD45RA+ in CD4+ 6 (3-11)  6 (2-12)  7 (2-18)  0.974 
Central memory Th cells  CCR7-CD45RA- in CD4+ 56 (23-70)  78 (40-82)  63 (52-84)  0.0377 
Effector memory Th cells  CCR7+CD45RA- in CD4+ 1 (0-2)  2 (1-3)  3 (1-4)  0.0222 
Terminal differentiated effector Th cells    CCR7-CD45RA+ in CD4+ 37 (18-65)  14 (10-46)  21 (13-38)  0.0561 
CD25-CD45RA+ in CD4+ 4 (0-6)  12 (3-15)  8 (2-15)  0.0187 










CD25+CD152+ in CD4+ 7 (3-13)  8 (3-16)  5 (3-22)  0.7697 
CD25+FoxP3+ in CD4+ 4 (2-11)  13 (9-24)  12 (4-23)  0.0097 
CD25+GITR+ in CD4+ 6 (2-11)  17 (9-23)  12 (5-38)  0.0105 
Granzyme B+ in CD4  2 (1-5)  3 (2-11)  3 (2-6)  0.1857 
TIA-1+ in CD4+ 7 (1-13)  10 (5-25)  7 (5-11)  0.2313 
CXCR5+ICOS+ in CD4+ 8 (5-27)  13 (9-47)  8 (4-24)  0.2501 
CD57+ in CD4+ 8 (3-22)  6 (3-20)  9 (3-17)  0.7307 
PD-1+ in CD4+ 30 (9-63)  22 (8-57)  34 (9-45)  0.7726 
PD-1+CD57+ in CD4+ 7 (2-21)  6 (2-18)  8 (2-16)  0.6881 
BCL6+CXCR5+ in CD4+ 12 (2-30)  9 (5-18)  9 (6-26)  0.6388 
BCL6+CD57+ in CD4+ 7 (3-15)  7 (3-15)  7 (2-12)  0.9766 
TFH regulatory cells  CD25+CXCR5+ICOS+ in CD4+ 31 (18-50)  44 (29-71)  46 (24-63)  0.2003 
Granzyme B+ in CD8+ 6 (4-27)  30 (18-57)  11 (8-18)  0.0035 
 





TIA-1+ in CD8+ 25 (19-49)  65 (44-92)  29 (26-44)  0.0017 
CXCR3+ in CD8+ 41 (20-63)  45 (23-74)  48 (39-78)  0.49 
CXCR4+ in CD8+ 21 (11-38)  28 (8-35)  25 (17-67)  0.8747 
CD16+ in CD56+ 4 (1-11)  8 (2-25)  1 (1-2)  0.003 
CD69+ in CD56+ 39 (23-72)  56 (13-90)  55 (32-83)  0.3225 
CD107a+ in CD56+ 1 (1-1)  1 (0-3)  2 (0-2)  0.3286 
NKT cells  CD56+CD16+ in CD3+ 4 (2-10)  7 (2-11)  5 (1-8)  0.7655 
 
Macrophages 
CD163+ 2 (1-7)  5 (2-11)  3 (1-5)  0.081 
CD163+ in CD68+ 17 (7-32)  34 (15-48)  32 (6-68)  0.1301 
K-W: Kruskal-Wallis Test; P values shown in bold indicate significant differences.
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